BUZZ-Oncolytics Biotech Inc: Presents cancer drug data at conference
** Canadian drug developer's U.S.-listed shares up 5 pct at $1.06 premarket
** Company presents data at a conference on a combination of its lead cancer drug along with radiationtherapy in treating melanoma, a type of skin cancer
** Data shows reolysin, when combined with radiationtherapy, effective in destroying cancer cells
** Reolysin was granted orphan drug status by U.S. FDA to treat a type of abdomen and fallopian tube cancer
** Orphan drug status is granted to drugs being developed to treat rare diseases; it gives drug developer various incentives including a 7-year marketing exclusivity
** Up to Wednesday's close, Oncolytics stock had gained 87 pct this year
© Thomson Reuters 2017 All rights reserved.